{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-103957","form_type":"8-K","ticker":"DMRA","cik":"0001800315","company_name":"Damora Therapeutics, Inc.","filed_at":"2024-09-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.558663+00:00","generated_at":"2026-05-31T06:17:21.028857+00:00","sec_items":["5.03","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Galecto effectuates 1-for-25 reverse stock split effective August 29, 2024","bullets":["Stockholders approved reverse split at June 20 special meeting; board set ratio at 1-for-25.","Every 25 pre-split shares converted into 1 share; fractional shares rounded up to whole share.","Outstanding stock options and equity plans proportionately adjusted; trading symbol GLTO unchanged.","New CUSIP number is 36322Q 206; split effective after market close on August 29, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-103957","json":"https://secwatch.observer/filing/0000950170-24-103957.json","markdown":"https://secwatch.observer/filing/0000950170-24-103957.md","text":"https://secwatch.observer/filing/0000950170-24-103957.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1800315/000095017024103957/0000950170-24-103957-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1800315/000095017024103957/glto-20240829.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T06:17:21.028857+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}